Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To assess the relative efficacy and metabolic effects of lurasidone and brexpiprazole in the acute treatment of schizophrenia. Methods: Five lurasidone and three brexpiprazole trials were identified. In the absence of head-to-head trials, a Bayesian network meta-analysis comparing lurasidone and brexpiprazole was performed. Results: Nonstatistically significant differences in efficacy measures were observed between lurasidone and brexpiprazole. Significant differences favoring lurasidone for weight change (-0.69 kg; 95% CrI: -1.22 to -0.15), total cholesterol (-7.60 mg/dl; 95% CrI: -13.94 to -1.22), and low-density lipoprotein (-6.58 mg/dl; 95% CrI: -12.11 to -1.04) were observed, with a trend indicating half the risk of experiencing ≥7% weight gain. Conclusion: This network meta-analysis suggested that lurasidone had similar efficacy and fewer metabolic effects than brexpiprazole in patients with acute schizophrenia.
Supplementary Material
File (supplementaryinformation.docx)
- Download
- 26.28 KB
References
Papers of special note have been highlighted as: • of interest
1.
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2(5), e141 (2005).
2.
van Os J, Kapur S. Schizophrenia. Lancet 374(9690), 635–645 (2009).
3.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Edition). American Psychiatric Publishing, Washington, DC, USA (2013).
4.
Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 13(5), 318–378 (2012).
5.
Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry 14(1), 2–44 (2013).
6.
Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
7.
Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry 13, 246 (2013).
8.
Velligan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 70(Suppl. 4), 1–46 (2009).
9.
Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatr. Serv. 55(8), 886–891 (2004).
10.
Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896), 951–962 (2013).
11.
Rummel-Kluge C, Komossa K, Schwarz S et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 38(1), 167–177 (2012).
12.
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13(1), 27–35 (2007).
13.
Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur. Neuropsychopharmacol. 17(4), 235–244 (2007).
14.
Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-related changed in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr. Res. 101(1–3), 287–294 (2008).
15.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 65(2), 267–272 (2004).
16.
Levitan B, Markowitz M, Mohamed AF et al. Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr. Serv. 66(7), 719–726 (2015).
17.
Parks J, Radke A, Parker G et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr. Bull. 35(5), 931–936 (2008).
18.
Godman B, De Bruyn K, Miranda J, Raschi E, Bennie M, Barbui C, Simoens S. Generic atypical antipsychotic drugs in Belgium: their influence and implications. J. Comp. Eff. Res. 2(6), 551–561 (2013).
19.
Godman B, Petzold M, Bennett K et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med. 12, 98 (2014).
20.
Ishibashi T, Horisawa T, Tokuda K et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 334(1), 171–181 (2010).
21.
Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8), 1400–1411 (2003).
22.
Das S, Barnwal P, Winston AB, Mondal S, Saha I. Brexpiprazole: so far so good. Ther. Adv. Psychopharmacol. 6(1), 39–54 (2016).
23.
Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int. Clin. Psychopharmacol. 31(4), 192–201 (2016).
• This is a brexpiprazole clinical trial used for this network meta-analysis.
24.
Centre for Reviews Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. (2009). www.york.ac.uk/media/crd/Systematic_Reviews.pdf
25.
Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8(5), 336–341 (2010).
26.
Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med. Inform. Decis. Mak. 7, 16 (2007).
27.
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Clinical Excellence (2011). www.ncbi.nlm.nih.gov/pubmedhealth/PMH0088912/pdf/PubMedHealth_PMH0088912.pdf
28.
Hoaglin DC, Hawkins N, Janse JP et al. Conducting indirect-treatment-comparison and network-meta-analysis studies; report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health 14, 429–437 (2011).
29.
Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence Synthesis for Decision Making in Healthcare. John Wiley and Sons, Ltd, Hoboken, NJ, USA (2012).
30.
Lunn DJ, Thomas A, Best N, Spiegelhalter D. Winbugs – a Baysesian modelling framework: concepts, structure, and extensibility. Stat. Comput. 10, 325–337 (2000).
31.
Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J. R. Stat. Soc. Ser. B Stat. Methodol. 64(4), 583–639 (2002).
32.
Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl.). 225(3), 519–530 (2013).
• This is a lurasidone clinical trial used for this network meta-analysis.
33.
Nakamura M, Ogasa M, Guarino J et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 70(6), 829–836 (2009).
• This is a lurasidone clinical trial used for this network meta-analysis.
34.
Nasrallah HA, Silva R, Phillips D et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J. Psychiatr. Res. 47(5), 670–677 (2013).
• This is a lurasidone clinical trial used for this network meta-analysis.
35.
Meltzer HY, Cucchiaro J, Silva R et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 168(9), 957–967 (2011).
• This is a lurasidone clinical trial used for this network meta-analysis.
36.
Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry 15, 271 (2015).
37.
Loebel A, Cucchiaro J, Sarma K et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr. Res. 145(1–3), 101–109 (2013).
• This is a lurasidone clinical trial used for this network meta-analysis.
38.
Citrome L, Cucchiaro J, Sarma K et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int. Clin. Psychopharmacol. 27(3), 165–176 (2012).
39.
Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RSE. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 127(1–3), 188–194 (2011).
40.
Tandon R, Cucchiaro J, Phillips D et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J. Psychopharmacol. 30(1), 69–77 (2016).
41.
McEvoy JP, Citrome L, Hernandez D et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J. Clin. Psychiatry 74(2), 170–179 (2013).
42.
Correll CU, Skuban A, Ouyang J et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 172(9), 870–880 (2015).
• This is a brexpiprazole clinical trial used for this network meta-analysis.
43.
Kane JM, Skuban A, Ouyang J et al. A multicenter, randomized, double-blind, controlled Phase III trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr. Res. 164(1–3), 127–135 (2015).
• This is a brexpiprazole clinical trial used for this network meta-analysis.
44.
Fleischhacker WW, Hobart M, Ouyang J et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 20(1), 11–21 (2017).
45.
Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68(Suppl. 1), 20–27 (2007).
46.
Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int. Clin. Psychopharmacol. 30(6), 342–350 (2015).
47.
Meyer JM, Ng-Mak DS, Chuang C-C, Rajagopalan K, Loebel A. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann. Gen. Psychiatry 16, 36 (2017).
48.
De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder. CNS Drugs 26(9), 733–759 (2012).
49.
Blackburn G. Effect of degree of weight loss on health benefits. Obes. Res. 3(Suppl. 2), S211–S216 (1995).
50.
Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, Phase II study of lurasidone in patients with acute schizophrenia. Ther. Adv. Psychopharmacol. 5(6), 322–331 (2015).
Information & Authors
Information
Published In
Pages: 737 - 748
PubMed: 29697278
Copyright
© 2018 Sunovion Pharmaceuticals Inc.
History
Received: 15 February 2018
Accepted: 12 April 2018
Published online: 26 April 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0016
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Srinivas Kamath, Alexander Hunter, Kate Collins, Anthony Wignall, Paul Joyce, The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats, British Journal of Pharmacology, 10.1111/bph.16507, 181, 22, (4531-4545), (2024).
- Valerio Ricci, Domenico De Berardis, Giuseppe Maina, Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review, Healthcare, 10.3390/healthcare12030339, 12, 3, (339), (2024).
- Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, Megan Elizabeth Good, Rif S. El-Mallakh, New Antipsychotic Medications in the Last Decade, Current Psychiatry Reports, 10.1007/s11920-021-01298-w, 23, 12, (2021).
- Shih-Ku Lin, Chin-Bin Yeh, Katsuhiko Hagi, Lurasidone Switching in Patients with Schizophrenia Who Showed Suboptimal Effect and/or Intolerability to Current Antipsychotics, Taiwanese Journal of Psychiatry, 10.4103/TPSY.TPSY_26_21, 35, 3, (132-139), (2021).
- Benjamin Kearns, Katy Cooper, Anna Cantrell, Chloe Thomas, Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain, Neuropsychiatric Disease and Treatment, 10.2147/NDT.S282856, Volume 17, (125-137), (2021).
- Lauren Stummer, Marija Markovic, Megan Maroney, Brexpiprazole in the Treatment of Schizophrenia and Agitation in Alzheimer’s Disease, Neurodegenerative Disease Management, 10.2217/nmt-2020-0013, 10, 4, (205-217), (2020).
- Yuan Feng, Jianguo Shi, Lili Wang, Xia Zhang, Yunlong Tan, Jingyuan Zhao, Yuping Ning, Shiping Xie, Xuejun Liu, Qi Liu, Keqing Li, Xiaoliang Wang, Lehua Li, Xiufeng Xu, Wei Deng, Xiaoyan Luo, Gang Wang, Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia, Psychiatry and Clinical Neurosciences, 10.1111/pcn.12965, 74, 6, (336-343), (2020).
- Filippo Corponi, Chiara Fabbri, Istvan Bitter, Stuart Montgomery, Eduard Vieta, Siegfried Kasper, Stefano Pallanti, Alessandro Serretti, Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone, European Neuropsychopharmacology, 10.1016/j.euroneuro.2019.06.008, 29, 9, (971-985), (2019).
- James E. Frampton, Brexpiprazole: A Review in Schizophrenia, Drugs, 10.1007/s40265-019-1052-5, 79, 2, (189-200), (2019).